G
Gervais Neliat
Researcher at Rhône-Poulenc
Publications - 14
Citations - 3265
Gervais Neliat is an academic researcher from Rhône-Poulenc. The author has contributed to research in topics: Receptor & Antagonist. The author has an hindex of 12, co-authored 14 publications receiving 3226 citations.
Papers
More filters
Journal ArticleDOI
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Murielle Rinaldi-Carmona,Francis Barth,Michel Heaulme,David Shire,Bernard Calandra,Christian Congy,Serge Martinez,Jeanne Maruani,Gervais Neliat,Daniel Caput,P. Ferrara,Philippe Soubrie,J. C. Breliere,Gérard Le Fur +13 more
TL;DR: SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor and should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.
Journal ArticleDOI
A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor.
X. Emonds-Alt,P. Vilain,Pierre Yves Andre Goulaouic,Vincenzo Proietto,D. Van Broeck,Charles Advenier,Emmanuel Naline,Gervais Neliat,G. Le Fur,J.C. Brelière +9 more
TL;DR: SR 48968 is a potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor and was a competitive antagonist of neurokinIn A-mediated contraction of different isolated smooth muscle preparations from various species including human.
Journal ArticleDOI
In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist
Xavier Emonds-Alt,Jean-Daniel Doutremepuich,Michel Heaulme,Gervais Neliat,Vincent Santucci,Régis Steinberg,P. Vilain,Daniel Bichon,Jean-Philippe Ducoux,Vincenzo Proietto,Didier Van Broeck,Philippe Soubrie,Gérard Le Fur,Jean-Claude Breliere +13 more
TL;DR: SR140333 potently, selectively and competitively inhibited substance P binding to NK1 receptors from various animal species, including humans, and exerted highly potent antagonism towardNK1 receptors in vitro and in vivo.
Journal ArticleDOI
SR 142801, The first potent non-peptide antagonist of the tachykinin NK3 receptor
X. Emonds-Alt,Daniel Bichon,Jean-Philippe Ducoux,Michel Heaulme,B. Miloux,M. Poncelet,Vincenzo Proietto,D. Van Broeck,P. Vilain,Gervais Neliat,Philippe Soubrie,G. Le Fur,J.C. Brele`ere +12 more
TL;DR: In vivo, SR 142801 potently inhibited the turning behaviour induced by intrastriatal injection of senktide in gerbils, and appears as a powerful tool for investigation of the physiological and pathological role of NKB and its NK3 receptor.
Journal ArticleDOI
SR120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist
Claudine Serradeil-Le Gal,Gerard Valette,Pierre-Eric Rouby,Alain Pellet,F. Oury-Donat,Gabrielle Brossard,Liliane Lespy,E. Marty,Gervais Neliat,Paul de Cointet,Jean-Pierre Maffrand,Gérard Le Fur +11 more
TL;DR: In vivo, by intravenous route, this compound acts as an antagonist in anesthetized guinea‐pigs and, notably, after oral administration, SR 120819A counteracts the pressor response of [Leu31,Pro34]NPY with a long duration of action, becoming the first orally‐effective NPY Y1 receptor antagonist yet descrobed.